In vitro Activity of Gepotidacin against Klebsiella pneumoniae, Including Molecularly Characterized ESBL and Carbapenemase Positive Subsets Causing Urinary Tract Infections in the United States (2019–2022)
<i>In vitro</i> Activity of Gepotidacin against <i>Klebsiella pneumoniae</i>, Including Molecularly Characterized ESBL and Carbapenemase Positive Subsets Causing Urinary Tract Infections in the United States (2019–2022). Lead author: Rodrigo E. Mendes, IDWeek 2024, October 16-19, Los Angeles, CA, USA
Poster #P1059
